

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Yestar Healthcare Holdings Company Limited

巨星醫療控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2393)

FULFILLMENT OF PROFIT GUARANTEE IN RELATION TO THE ACQUISITIONS

Profit Guarantee in relation to the Acquisition of Yestar Biotech (Jiangsu) Company Limited

Reference is made to the announcement of Yestar Healthcare Holdings Company Limited (the “Company”) dated 12 September 2014 and the circular of the Company dated 24 October 2014 (the “First Circular”) in respect of, amongst other things, the acquisition of 70% equity interests in Yestar Biotech (Jiangsu) Company Limited (“Yestar Biotech (Jiangsu)”) (formerly known as “Jiangsu Uno Technology Development Company Limited”). Capitalised terms used herein shall have the same meanings as defined in the First Circular unless the context herein requires otherwise.

Pursuant to the Share Transfer Agreement, the Vendors, namely Ms. Hang and Ms. Xu, irrevocably and unconditionally guaranteed that 2016 Net Profit (the audited consolidated net profit after taxation for the year ended 31 December 2016 in accordance with the International Financial Reporting Standards (“IFRS”)) of Yestar Biotech (Jiangsu) shall not be less than RMB64,000,000.

The Board is pleased to announce that the 2016 Net Profit of Yestar Biotech (Jiangsu) is more than the Annual Guarantee Profit of RMB64,000,000 for the year ended 31 December 2016. As the aforesaid Annual Guarantee Profit has been fulfilled, no compensation is required to be paid by Ms. Hang and Ms. Xu to the Company pursuant to the Share Transfer Agreement.

Profit Guarantee in relation to the Acquisition of Shanghai Emphasis Group Companies

Reference is also made to the announcement of the Company dated 10 April 2015 and the circular of the Company dated 30 June 2015 (the “Second Circular”) in respect of, amongst other things, the acquisition of 70% equity interests in Target Companies, namely Shanghai Emphasis Investment, Shanghai Jianchu Medical, Shanghai Chaolian Trading, Shanghai Haole Industrial and Shanghai Dingpei Industrial. Capitalised terms used herein shall have the same meanings as defined in the Second Circular unless the context herein requires otherwise.

Pursuant to the Share Transfer Agreement, Mr. Li Bin irrevocably and unconditionally guaranteed that 2016 Net Profit (the combined net profits after taxation for the year ended 31 December 2016 in accordance with the IFRS) of the Target Companies shall not be less than RMB187,000,000.

The Board is pleased to announce that the 2016 Net Profit of the Target Companies is more than the Annual Guarantee Profit of RMB187,000,000 for the year ended 31 December 2016. As the aforesaid Annual Guarantee Profit has been fulfilled, no compensation is required to be paid by Mr. Li Bin to the Company pursuant to the Share Transfer Agreement.

By Order of the Board
Yestar Healthcare Holdings Company Limited
巨星醫療控股有限公司
Hartono James
Chairman, CEO and Executive Director

Hong Kong, 15 March 2017

As at the date of this announcement, the executive Directors are Mr. Hartono James, Ms. Wang Ying, Mr. Chan To Keung, Ms. Wang Hong and Mr. Chan Chung Man; and the independent non-executive Directors are Dr. Hu Yiming, Mr. Karsono Tirtamarta (Kwee Yoe Chiang) and Mr. Sutikno Liky.